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OBJECTIVES: The current study aimed to review published Burden of Disease (BOD) 
studies performed in 12 selected countries and economic entities in the Asia-Paciﬁ c 
(AP) region since 1993, when the ﬁ rst Global Burden of Disease (GBD) report
appeared. METHODS: Electronic databases and bibliographic searching techniques
were utilized. Four databases, Medline, EMBASE, EconLit and Cochrane Database, 
were involved in the primary search from 1993–2008. Titles and abstracts were 
reviewed using predeﬁ ned criteria to select potential articles for further review. Rele-
vant BOD studies were classiﬁ ed into three levels (Levels I, II and III) from least to 
most informative for evidence-based health policy decision according to the inclusion 
of the number of the three elements, namely, the epidemiology, humanistic and eco-
nomic burden of the disease, which are normally involved in the measurement of BOD.
RESULTS: From 1245 retrieved references, 419 articles were selected for review; of 
which 308 were classiﬁ ed as Level I as being least informative BOD studies from health 
policy maker’s perspective. In the remaining 108 articles classiﬁ ed as level II, 74 of 
them were cost-of-illness (COI) studies and 34 of them adopted the summary indica-
tors including disability-adjusted life year (DALY). Only 3 articles estimated the BOD
with all three elements and were classiﬁ ed at Level III as most informative BOD 
studies. Among the 74 COI studies covering 41 diseases, 45 of them considered the 
indirect costs in addition to direct costs, with only one estimated intangible costs in
monetary value. An unbalance of BOD research output among selected countries was 
observed. CONCLUSIONS: Estimating BOD comprehensively is a complex task and 
the paucity of speciﬁ c studies in AP region needs to be addressed. In order to improve 
the quality of research, a clear deﬁ nition of BOD study from health policy makers’
perspective would be necessary.
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OBJECTIVES: The objective of this study was to utilize hospital EMR data to study
severe sepsis, including the timing of organ dysfunction and source of infection. These
study variables are needed to fully investigate clinical and economic outcomes in severe 
sepsis. METHODS: Inpatient, pharmacy, laboratory, and UB-92 billing data from
Cerner’s Health Facts database January 1, 2001 – September 30, 2007 were used.
Qualifying patients had an inpatient encounter with a primary or secondary diagnosis 
of sepsis (ICD-9-CM code: 038.x, 040.82, 785.52, 995.91, 995.92) AND evidence of 
q1 acute organ system dysfunction within 24 hours prior to index blood culture
through 3 days post admission AND an order for a blood culture and IV antibiotic
within o24 hours of admission. Organ dysfunction was deﬁ ned to be consistent with
a Sequential Organ Failure Assessment score of q2 for the following categories: respi-
ratory, hematologic, hepatic, cardiovascular, and renal. Sepsis source was identiﬁ ed by 
ICD-9. RESULTS: 11,761 patients met the study deﬁ nition of severe sepsis. The mean 
age was 69 years and 43% were 75 years old or older. Cardiovascular (51%), renal
(51%) and respiratory (49%) dysfunctions were the most common organ dysfunctions 
in the study cohort. Approximately 70% had 1 or 2 organ dysfunctions; 26% had
three or four organ dysfunctions; only 3% had all 5 organ dysfunctions. The sequence 
of organ dysfunction (median time from index blood culture) was as follows: respira-
tory  cardiovascular  renal  hepatic  hematologic. Nearly half of the patients had 
either multiple or unknown sources of infection followed by respiratory (20%), geni-
tourinary (14%), gastrointestinal (8%), and skin/soft tissue (6%). CONCLUSIONS:
Hospital EMR data can be used to study severe sepsis, including patterns of organ
dysfunction and source of infection. Additional research can quantify burden-of-illness
by source of sepsis and lead to earlier recognition of developing sepsis.
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OBJECTIVES: Using routinely collected administrative health care claims and medical 
encounter data for observational studies for post marketing evidence generation holds
considerable promise. These studies rely heavily on the validity and accuracy of diag-
nosis coding. The objective of this pilot study was to assess the extent of within and
across health system variation in diagnosis coding. METHODS: Two ICD-9 diagnosis 
categories were selected for review: 557 (vascular insufﬁ ciency of intestine) and 708 
(urticaria). Each category contained speciﬁ c codes that have been used in observational 
studies using administrative claims data. The annual frequency for all subcategories
from 2000–2007 was collected from nine HMO Research Network health plans 
(sites). The frequency of each 4-digit code within each category was compared across
years and sites. Speciﬁ cally, we assessed within-site and cross-site coding variation of 
subcategories 557.0 (acute vascular insufﬁ ciency of intestine) and 708.0 (allergic urti-
caria). RESULTS: From 2000–2007, 54,395 diagnoses within the 557 category and 
419,428 diagnoses within the 708 category were identiﬁ ed. Each year, subcategory 
557.0 accounted for 37–46% of all 557 coding and subcategory 708.0 accounted for
12–13% of all 708 coding; this varied widely within and across sites. In 2007 subcat-
egory 557.0 accounted for a low of 24% of 557 diagnoses at one site and a high of 
53% at a different site; similar variation was observed in all study years. In the same
year, subcategory 708.0 accounted for a low of 5% of 708 diagnoses at one site and 
a high of 20% at a different site; similar variation was also observed in all study years.
CONCLUSIONS: Our results indicate substantial variation in ICD-9 coding across
time and health systems. Studies using administrative encounter data should carefully
consider the extent and effect of coding variation when using speciﬁ c ICD-9 subcatego-
ries to deﬁ ne inclusion/exclusion criteria or study outcomes.
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OBJECTIVES: Both inpatient data and outpatient data are logically required to 
study the continuum of care before, during, and after hospitalization. To create 
such a repository of longitudinal patient-level information, data extracted from a 
large US hospital database were matched to a large single-payer claims database. The 
purpose of this methodological study was to determine which steps in the method
were inﬂ uential toward optimizing the quality and quantity of matched patient 
data. METHODS: Hospital data were drawn from the Premier Perspective™
Database, a large de-identiﬁ ed US hospital clinical and economic database developed
for quality and utilization benchmarking. Claims data were drawn from a large 
national health plan and provided by i3 Pharma Informatics. De-identiﬁ ed inpatient
discharges and outpatient services rendered from January 2005 through December 
2007. Inpatient hospitals were matched to the health plan hospitals on Medicare 
provider number and provider name and address. All claims (hospital, physician, 
lab, pharmacy) during the timeframe were retrieved and matching episodes of 
care were deﬁ ned as claims-level “discharges” based on the available list of variables:
provider number, admit date, discharge date, DRG or MS-DRG, gender, and birth
date. RESULTS: The inpatient database contained 447 of the 730 matched providers,
representing 16.7 million discharges (not limited to the claims data payer). Initial
matching linked 355,590 claims-level discharges to 389,482 hospital-level discharges
based on the deﬁ nition of “discharge”. Removing duplicate matches yielded 335,481 
one-to-one matched discharges, representing 275,138 unique patients. The ﬁ nal 
linked and cleaned data extract contains 331,814 discharges, representing 275,138
unique patients. CONCLUSIONS: A series of detailed steps and interim quality 
checks optimizes the quality and quantity of matched patients for use in subsequent 
outcomes research. Linking the hospital data to claims data leverages both datasets
to enable more robust understanding of patient-level continuum of care than non-
linked data.
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OBJECTIVES: Post-marketing surveillance for adverse effects has become an essential
element of new drug and medical devices development in the European Union and the 
United States, especially after the withdrawals of drugs such as cerivastatin and rofe-
coxib due to major safety issues. Post-marketing surveillance studies (PMS) are used 
to gather additional information about product safety, efﬁ cacy or optimal use. Regula-
tory Post-Marketing Studies (RPMS) are those requested by regulatory agencies and
that the sponsor agrees to conduct to provide additional information concerning the
approved product. A database gathering the details of proposed and ongoing RPMS
would provide the different stakeholders with a better understanding of previous
post-marketing requirements for drugs and medical devices. In addition this informa-
tion would enable product manufacturers to anticipate regulatory requests. Such a 
database is currently being developed in the manner described below. METHODS:
Information about RPMS requested since 2000 is being gathered from different regula-
tory agency sources including, the Haute Autorité de Santé – HAS (France), the
European Medicines Agency – EMEA (EU) and the Food and Drug Administration –
FDA (USA). The following categories will be displayed for each product in the data-
base: product description, application details, pharmacological action, information 
source and RPMS details, with a link to the source documents. The search facilities 
will include these ﬁ elds among many others. The database will be available online in 
an independent website, with access by subscription. RESULTS: Preliminary results
will be presented describing the development and current content of the database. 
CONCLUSIONS: This project will be a unique source of centralized information 
about RPMS requested in Europe and in the US. It will be useful to observe the current 
trends in studies requested, to anticipate the demands, and to integrate the studies as 
early as possible in the product development process.
